Recurrent Glioblastoma Multiforme Treatment Market
- 2026 年市場規模
- USD 3.5 Bn
- 2033 年預估規模
- USD 5.37 Bn
- 年複合成長率 CAGR
- 8.35%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Recurrent Glioblastoma Multiforme Treatment Market, By Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, Chemotherapy ), By Type (Grade II or Grade III, Grade IV, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
Glioblastoma multiforme or GBM is an aggressive and the most common form of brain cancer that involves glial cells. Gliomas are rapidly developing tumors that develop from the star-shaped glial cells present in the spinal cord or brain. Recurrent glioblastoma multiforme is a possibility of reoccurrence of GBM after tumor surgery. This is because it is difficult to wholly remove the tumor during surgery and there is always a possibility that after a period of remission, cancer might recur. The symptoms of GBM include constant headaches, seizures, vomiting, difficulty in speaking, and double or blurred vision.
Market Dynamics
The rising incidence of brain cancers is expected to drive the recurrent glioblastoma multiforme treatment market growth over the forecast period. Although, researchers believe that egentic mutations may cause this disease, symptoms include seizures, change in mood, loss of appetite, double or blurred vision, change in ability to think and difficulty in speech. According to the statistics provided by the World Health Organization (WHO), each year, around 5 million people are diagnosed with epilepsy across the globe.
Moreover, tuberous sclerosis, neurofibromatosis, von-hippel-lindau disease, turcot syndrome, and Li-fraumeni syndrome are some of the genetic disorders related to the increasing prevalence of gliomas, which is expected to fuel the market growth during the forecast period.
Furthermore, key players in the market are increasingly investing in research & development to develop, create, and commercialize novel drugs, which is expected to create lucrative growth opportunities for the global recurrent glioblastoma multiforme treatment market in the near future. However, lack of effective therapies and the inability of drugs to effectively prevent tumor reoccurrence are predicted to restrict the market growth over the forecast period.
Key features of the study
• This report provides in-depth analysis of the global recurrent glioblastoma multiforme treatment market, market size (USD Bn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026-2033, considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global recurrent glioblastoma multiforme treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
• Key players covered as a part of this study include GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.
• Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global recurrent glioblastoma multiforme treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for recurrent glioblastoma multiforme treatment market, research and consulting firms, new entrants, and financial analysts.
Market Segmentation
• By Treatment
o Oral Medications
o Radiosensitizers
o Nitrosoureas Drugs
o Chemotherapy
• By Type
o Grade II or Grade III
o Grade IV
o Others
• By Region
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East & Africa
GCC Countries
Israel
Rest of Middle East & Africa
• Key Players
o GlaxoSmithKline plc.
o AstraZeneca
o Hoffman-La Roche, Ltd.
o Pfizer, Inc.
o Merck & Co., Inc.
o Vascular Biogeneics
o AngioChem, Inc.
o Boehringer Ingelheim GmbH
o Bristol-Myers Squibb Company
o Boston Biomedical, Inc.
o Cantex Pharmaceuticals, Inc.
o Celldex Therapeutics, Inc.
o Cavion LLC
o Coherus BioSciences, Inc.
o Eisai
o Eli Lilly and Company
o Cortice Biosciences, Inc.
o EnGeneIC Ltd.
o GenSpera, Inc.
o ERC Belgium SA
o Genzyme Corporation
o ImmunoCellular Therapeutics, Ltd.
o GW Pharmaceuticals Plc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Treatment
Market Snapshot, By Type
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment, 2026 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2026– 2033
Segment Trends
o Oral Medications
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
o Radiosensitizers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
o Nitrosoureas Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
o Chemotherapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
5. Global Recurrent Glioblastoma Multiforme Treatment Market, By Type, 2026 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2026 – 2033
Segment Trends
o Grade II or Grade III
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
o Grade IV
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)
6. Global Recurrent Glioblastoma Multiforme Treatment Market, By Region, 2026 – 2033, (USD Bn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2026–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 – 2033, (USD Bn)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
GlaxoSmithKline plc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
AstraZeneca
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
F. Hoffman-La Roche, Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer, Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Merck & Co Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Vascular Biogeneics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
AngioChem, Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Boehringer Ingelheim GmbH
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Bristol-Myers Squibb Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Boston Biomedical, Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Cantex Pharmaceuticals, Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Celldex Therapeutics, Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Cavion LLC
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Cavion LLC
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Eisai
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Eli Lilly and Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Cortice Biosciences, Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Market Strategies
EnGeneIC Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Market Strategies
GenSpera, Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Market Strategies
ERC Belgium SA
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Market Strategies
Genzyme Corporation
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Market Strategies
ImmunoCellular Therapeutics, Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Market Strategies
GW Pharmaceuticals Plc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們